Siemens Energy Q3 Profit Beats Forecast as AI-Driven Power Demand Fuels Growth 
Novo Nordisk Raises 2025 Outlook Despite Wegovy Pill Miss and CagriSema Setback 
Nvidia to Invest Up to $3 Billion in Blackstone-Backed Lancium 
Alibaba Plans Revenue-Sharing Model for Qwen3.8-Max AI Commercial Users 
SpaceX Targets Starship Flight 14 With First V3 Starlink Satellite Launch 
Daimler Truck Q2 Profit Falls 18%, 2026 Outlook Raised 
Heineken H1 Operating Profit Meets Forecast as Beer Volumes Beat Expectations 
Western Digital Q4 Earnings Beat Estimates as FY2027 Outlook Tops Expectations 
Qantas Shares Climb as Long-Haul Pilot Deal Eases Strike Concerns 
Glencore Posts Strong H1 2026 Earnings, Announces ASX Secondary Listing 
Alphabet Stock Slides as Google AI Pioneer Jeff Dean Exits to Launch Discovery Loop 
DBS Raises 2025 Outlook After Record Q2 Profit Driven by Wealth Management 
Cloudflare Stock Jumps 15% as Earnings Beat Estimates, 2026 Outlook Raised 
DeepSeek to Raise AI API Prices as Demand for New Models Surges 
DHL Q2 Profit Jumps 24% as Express Business Drives Growth 
OpenAI Restricts Astra AI Over Cyberattack Risks 
Meta AI Model Exploits Security Flaw During Cybersecurity Test, Raising AI Safety Concerns 
CHESTERBROOK, Pa., March 07, 2018 -- Trevena, Inc. (NASDAQ:TRVN) today announced that it will be presenting at the Cowen and Company 38th Annual Healthcare Conference on Wednesday, March 14, 2018, at 8:40 a.m. ET in Boston, MA.
To join a live audio webcast of the presentation, please visit the Investor section of the Company’s website. Following the conclusion of the presentation, the webcast will be available for replay for 30 days.
About Trevena
Trevena, Inc. is a biopharmaceutical company focused on providing better, safer therapies to patients in pain. The Company has leveraged breakthrough science to discover and develop its investigational product OLINVO™ (oliceridine) Injection for the management of moderate-to-severe acute pain. OLINVO has been granted Breakthrough Therapy designation by the U.S. Food and Drug Administration, and is intended to provide healthcare providers an innovative new option for patients who require an intravenous opioid. The Company also has an early stage pipeline of new chemical entities targeting novel mechanisms of action, including TRV250 for acute migraine, neuropathic pain, and other indications.
Contacts
Trevena, Inc.
Investors:
Jonathan Violin, Ph.D.
Senior Vice President, Scientific Affairs & Investor Relations Officer
610-354-8840 x231
[email protected]
or
Media:
Public Relations
[email protected]
